Lupin subsidiary acquires 9 brands South African firm

Lupin's subsidiary, in partnership with ImpiloVest, has acquired nine brands from MNI in South Africa, enhancing its portfolio in complementary and alternative medicines. The acquired brands address various health issues, aligning with Lupin's commitment to holistic and sustainable healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/o6Pi3Za
via IFTTT

Read More

Quick access to key HIV drug hinges on waiver of local clinical trials: Experts

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic versions. They must apply for waivers to supply the drug locally and in 120 low- and middle-income countries. Approval from the drug regulator is crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35L7eW2
via IFTTT

Read More

Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir

Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0jB2cKg
via IFTTT

Read More

CCI clears Rs 13,630 cr Mankind Pharma acquisition of Bharat Serums

The Competition Commission of India (CCI) has approved Mankind Pharma's ₹13,630-crore acquisition of Bharat Serums and Vaccines. This acquisition will strengthen Mankind's position in the Indian women's health and fertility drug market. Mankind Pharma and Bharat Serums both specialize in pharmaceutical formulations and healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WZEcsIU
via IFTTT

Read More

Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug

Dr. Reddy’s has partnered with Gilead Sciences to manufacture and market the HIV drug Lenacapavir in India and 120 other countries. The agreement includes developing Lenacapavir for both treatment and potential prevention of HIV. This collaboration aims to make this advanced treatment accessible in regions with high HIV burdens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HZbqXu5
via IFTTT

Read More

CCI clears Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines deal

The Competition Commission of India has approved Mankind Pharma's Rs 13,630 crore acquisition of Bharat Serums and Vaccines. This acquisition, which includes a 100% stake, advances Mankind Pharma's position in the women's health and fertility drug market and grants access to critical care products with established R&D platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bRyXsdU
via IFTTT

Read More

Government looking to tweak regulatory norms for MedTech, pharma sectors: Niti Aayog's VK Paul

The Indian government is considering regulatory revisions for the MedTech and pharma sectors and has sought input from the industry. Niti Aayog member VK Paul highlighted the need to update the regulatory framework to support advancements in medical technology and pharma, aiming for enhanced exports and innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QyVP3OY
via IFTTT

Read More